Skip to main content

Clinical Trials Using Lenvatinib Mesylate

Review the clinical trials studying lenvatinib mesylate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-7 of 7

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Status: Active
Location: 8 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Pembrolizumab and Lenvatinib for the Treatment of Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, and Other Tumors with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania